Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03130764
Title Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Adrian Sacher

lung non-small cell carcinoma


Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries

Additional content available in CKB BOOST